Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral formulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherenc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Patient Prefer Adherence
Autori principali: Tchobaniouk, Lesia V, McAllister, Erin E, Bishop, Danielle L, Carpentier, Rachel M, Heins, Katharine R, Haight, Robert J, Bishop, Jeffrey R
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2019
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053417/
https://ncbi.nlm.nih.gov/pubmed/32184570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S192418
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi